Publications by authors named "B E Blue"

Claim this Profile
D
Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab.
M Bakri Hammami, Sean P Haney, Danny DeAvila, Julia Fadul, Christine E Simonelli, Brandon Blue

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.
Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Doris K Hansen, Brandon Blue

Front Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
Mark B Meads, Xiaohong Zhao, David R Noyes, Praneeth Sudalagunta, Alexandra Achille, Brandon J Blue

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma.
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, Lauren C Peres, Christelle M Colin-Leitzinger, Brandon Blue

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma.
Stefanie Palfi, Lauren C Peres, Himara Koelmeyer, Melissa Alsina, Rachid C Baz, Brandon J Blue

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis